Antiplatelet effect of aspirin in patients with coronary artery disease

Danish Medical Journal

Volumn 59, Issue 9, 2012, Pages

  Grove, Erik Lerkevang ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; HJERDYL; PADGEM PROTEIN; PROSTAGLANDIN SYNTHASE; THROMBOPOIETIN; THROMBOXANE; UNCLASSIFIED DRUG;

ANGIOGRAPHY; ARTICLE; BLOOD CLOTTING; BLOOD CLOTTING TEST; CORONARY ARTERY DISEASE; ELECTROCARDIOGRAPHY; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HUMAN; INTERMETHOD COMPARISON; LIGHT TRANSMISSION AGGREGOMETRY; MULTIPLE ELECTRODE AGGREGOMETRY; PATELET FUNCTION ANALYSER; PATIENT ATTITUDE; RADIOIMMUNOASSAY; REPRODUCIBILITY; ST SEGMENT; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOCYTE COUNT; THROMBOCYTE FUNCTION; THROMBOCYTE METABOLISM;

EID: 84873270735     PISSN: None     EISSN: 22451919     Source Type: Journal    
DOI: None     Document Type: Article

References (258)

1. World Health Organization: Fact sheet No 317: Cardiovascular diseases. January 2011 http://www.who.int/mediacentre/factsheets/fs317/en/ index.html (accessed 25-7-2011).
2. Fuster V, Badimon L, Badimon JJ et al. The pathogenesis of coronary artery disease and the acute coronary syndromes (part 1). N Engl J Med 1992; 326:242-250.
3. Grove EL, Kristensen SD. Update on oral antiplatelet therapy: principles, problems and promises. Future Cardiol 2009; 5:247-258.
4. Mackay J, Mensah G. Atlas of Heart Disease and Stroke. 1 ed. World Health Organization. 2004; 1-112.
5. Platelets. Second ed. Academic Press/Elsevier. 2007; 1-1343.
6. George JN. Platelets. Lancet 2000; 355:1531-1539.
7. Italiano JE, Jr., Hartwig JH. Megakaryocyte Development and Platelet Formation. In: Michelson AD, ed. Platelets. Second ed. Academic Press/Elsevier; 2007. p. 23-44.
8. Bonello L, Camoin-Jau L, Arques S et al. Adjusted clopidogrel loading doses according to vasodilatorstimulated phosphoprotein phosphorylation index decrease rate of major adverse cardiovascular events in patients with clopidogrel resistance: a multicenter randomized prospective study. J Am Coll Cardiol 2008; 51:1404-1411.
9. Kaushansky K. Determinants of platelet number and regulation of thrombopoiesis. Hematology Am Soc Hematol Educ Program 2009; 147-152.
10. Behnke O, Forer A. From megakaryocytes to platelets: platelet morphogenesis takes place in the bloodstream. Eur J Haematol Suppl 1998; 61:3-23.
11. Kaushansky K. Thrombopoietin: the primary regulator of platelet production. Blood 1995; 86:419-431.
12. Kutor DJ. Platelet Growth Factors. In: Michelson AD, ed. Platelets. Second ed. Academic Press/Elsevier; 2007. p. 1211-1236.
13. Martin JF, Trowbridge EA, Salmon G et al. The biological significance of platelet volume: its relationship to bleeding time, platelet thromboxane B2 production and megakaryocyte nuclear DNA concentration. Thromb Res 1983; 32:443-460.
14. Brown AS, Martin JF. The megakaryocyte platelet system and vascular disease. Eur J Clin Invest 1994; 24 Suppl 1:9-15.
15. Ault KA, Rinder HM, Mitchell J et al. The significance of platelets with increased RNA content (reticulated platelets). A measure of the rate of thrombopoiesis. Am J Clin Pathol 1992; 98:637-646.
16. Briggs C, Kunka S, Hart D et al. Assessment of an immature platelet fraction (IPF) in peripheral thrombocytopenia. Br J Haematol 2004; 126:93-99.
17. Harrison P, Robinson MS, Mackie IJ et al. Reticulated platelets. Platelets 1997; 8:379-383.
18. Takami A, Shibayama M, Orito M et al. Immature platelet fraction for prediction of platelet engraftment after allogeneic stem cell transplantation. Bone Marrow Transplant 2007.
19. Ingram M, Coopersmith A. Reticulated platelets following acute blood loss. Br J Haematol 1969; 17:225-229.
20. Cesari F, Marcucci R, Caporale R et al. Relationship between high platelet turnover and platelet function in high-risk patients with coronary artery disease on dual antiplatelet therapy. Thromb Haemost 2008; 99:930-935.
21. Lindemann S, Gawaz M. The active platelet: translation and protein synthesis in an anucleate cell. Semin Thromb Hemost 2007; 33:144-150.
22. Dale GL, Friese P, Hynes LA et al. Demonstration that thiazole-orange-positive platelets in the dog are less than 24 hours old. Blood 1995; 85:1822-1825.
23. Ault KA, Knowles C. In vivo biotinylation demonstrates that reticulated platelets are the youngest platelets in circulation. Exp Hematol 1995; 23:996-1001.
24. Guthikonda S, Lev EI, Patel R et al. Reticulated platelets and uninhibited COX-1 and COX-2 decrease the antiplatelet effects of aspirin. J Thromb Haemost 2007; 5:490-496.
25. Kieffer N, Guichard J, Farcet JP et al. Biosynthesis of major platelet proteins in human blood platelets. Eur J Biochem 1987; 164:189-195.
26. Guthikonda S, Alviar CL, Vaduganathan M et al. Role of reticulated platelets and platelet size heterogeneity on platelet activity after dual antiplatelet therapy with aspirin and clopidogrel in patients with stable coronary artery disease. J Am Coll Cardiol 2008; 52:743-749.
27. Grove EL, Kristensen DS. Stent thrombosis: definitions, mechanisms and prevention. E-journal of Cardiology Practice 2007; 5:1-4.
28. DeWood MA, Spores J, Notske R et al. Prevalence of total coronary occlusion during the early hours of transmural myocardial infarction. N Engl J Med 1980; 303:897-902.
29. Mizuno K, Satomura K, Miyamoto A et al. Angioscopic evaluation of coronary-artery thrombi in acute coronary syndromes. N Engl J Med 1992; 326:287-291.
30. Akasaka T, Kubo T, Mizukoshi M et al. Pathophysiology of acute coronary syndrome assessed by optical coherence tomography. J Cardiol 2010; 56:8-14.
31. Falk E. Unstable angina with fatal outcome: dynamic coronary thrombosis leading to infarction and/or sudden death. Autopsy evidence of recurrent mural thrombosis with peripheral embolization culminating in total vascular occlusion. Circulation 1985; 71:699-708.
32. Davies MJ, Thomas AC, Knapman PA et al. Intramyocardial platelet aggregation in patients with unstable angina suffering sudden ischemic cardiac death. Circulation 1986; 73:418-427.
33. Libby P. Inflammation in atherosclerosis. Nature 2002; 420:868-874.
34. Kristensen SD, Andersen HR, Falk E. What an interventional cardiologist should know about the pathophysiology of acute myocardial infarction. Semin Interv Cardiol 1999; 4:11-16.
35. Holme PA, Orvim U, Hamers MJ et al. Shear-induced platelet activation and platelet microparticle formation at blood flow conditions as in arteries with a severe stenosis. Arterioscler Thromb Vasc Biol 1997; 17:646-653.
36. Storey RF. Biology and pharmacology of the platelet P2Y12 receptor. Curr Pharm Des 2006; 12:1255-1259.
37. Grove EL, Orntoft TF, Lassen JF et al. The platelet polymorphism PlA2 is a genetic risk factor for myocardial infarction. J Intern Med 2004; 255:637-644.
38. Ware JA, Heistad DD. Seminars in medicine of the Beth Israel Hospital, Boston. Platelet-endothelium interactions. N Engl J Med 1993; 328:628-635.
39. Craven LL. Experiences with aspirin (acetylsalicylic acid) in the nonspecific prophylaxis of coronary thrombosis. Mississippi Valley Medical Journal 1953; 75:38-44.
40. Miner J, Hoffhines A. The discovery of aspirin's antithrombotic effects. Tex Heart Inst J 2007; 34:179-186.
41. Weiss HJ, Aledort LM. Impaired platelet-connectivetissue reaction in man after aspirin ingestion. Lancet 1967; 2:495-497.
42. Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol 1971; 231:232-235.
43. Vane JR, Bakhle YS, Botting RM. Cyclooxygenases 1 and 2 Annu Rev Pharmacol Toxicol 1998; 38:97-120.
44. Pedersen AK, FitzGerald GA. Dose-related kinetics of aspirin. Presystemic acetylation of platelet cyclooxygenase. N Engl J Med 1984; 311:1206-1211.
45. Cox D, Maree AO, Dooley M et al. Effect of enteric coating on antiplatelet activity of low-dose aspirin in healthy volunteers. Stroke 2006; 37:2153-2158.
46. Roth GJ, Stanford N, Majerus PW. Acetylation of prostaglandin synthase by aspirin. Proc Natl Acad Sci U S A 1975; 72:3073-3076.
47. Patrono C, Garcia Rodriguez LA, Landolfi R et al. Lowdose aspirin for the prevention of atherothrombosis. N Engl J Med 2005; 353:2373-2383.
48. Patrignani P, Filabozzi P, Patrono C. Selective cumulative inhibition of platelet thromboxane production by lowdose aspirin in healthy subjects. J Clin Invest 1982; 69:1366-1372.
49. Patrono C, Ciabattoni G, Pinca E et al. Low dose aspirin and inhibition of thromboxane B2 production in healthy subjects. Thromb Res 1980; 17:317-327.
50. Perneby C, Wallen NH, Rooney C et al. Dose-and timedependent antiplatelet effects of aspirin. Thromb Haemost 2006; 95:652-658.
51. Hedegaard SS, Hvas AM, Grove EL et al. Optical platelet aggregation versus thromboxane metabolites in healthy individuals and patients with stable coronary artery disease after low-dose aspirin administration. Thromb Res 2009; 124:96-100.
52. FitzGerald GA. Mechanisms of platelet activation: thromboxane A2 as an amplifying signal for other agonists. Am J Cardiol 1991; 68:11B-15B.
53. Fitzgerald DJ, Maree A. Aspirin and clopidogrel resistance. Hematology Am Soc Hematol Educ Program 2007; 2007:114-120.
54. Rocca B, Secchiero P, Ciabattoni G et al. Cyclooxygenase-2 expression is induced during human megakaryopoiesis and characterizes newly formed platelets. Proc Natl Acad Sci U S A 2002; 99:7634-7639.
55. Awtry EH, Loscalzo J. Aspirin. Circulation 2000; 101:1206-1218.
56. Kuster LJ, Frolich JC. Platelet aggregation and thromboxane release induced by arachidonic acid, collagen, ADP and platelet-activating factor following low dose acetylsalicylic acid in man. Prostaglandins 1986; 32:415-423.
57. Patrono C, Coller B, FitzGerald GA et al. Platelet-active drugs: the relationships among dose, effectiveness, and side effects: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126:234S-264S.
58. Roth GJ, Majerus PW. The mechanism of the effect of aspirin on human platelets. I. Acetylation of a particulate fraction protein. J Clin Invest 1975; 56:624-632.
59. Moroz LA. Increased blood fibrinolytic activity after aspirin ingestion. N Engl J Med 1977; 296:525-529.
60. Ajjan R, Storey RF, Grant PJ. Aspirin resistance and diabetes mellitus. Diabetologia 2008; 51:385-390.
61. Undas A, Brummel-Ziedins KE, Mann KG. Antithrombotic properties of aspirin and resistance to aspirin: beyond strictly antiplatelet actions. Blood 2006.
62. ISIS-2 (Second International Study of Infarct Survival) CollaborativeGroup. Randomized trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. J Am Coll Cardiol 1988; 12:3A-13A.
63. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002; 324:71-86.
64. Buch MH, Prendergast BD, Storey RF. Antiplatelet therapy and vascular disease: an update. Therapeutic Advances in Cardiovascular Disease 2010; 4:249-275.
65. Agarwal S, Coakley M, Reddy K et al. Quantifying the effect of antiplatelet therapy: a comparison of the platelet function analyzer (PFA-100) and modified thromboelastography (mTEG) with light transmission platelet aggregometry. Anesthesiology 2006; 105:676-683.
66. Baigent C, Blackwell L, Collins R et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 2009; 373:1849-1860.
67. Patrono C, Bachmann F, Baigent C et al. Expert consensus document on the use of antiplatelet agents. The task force on the use of antiplatelet agents in patients with atherosclerotic cardiovascular disease of the European society of cardiology. Eur Heart J 2004; 25:166-181.
68. Becker RC, Meade TW, Berger PB et al. The primary and secondary prevention of coronary artery disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133:776S-814S.
69. US Preventive Services Task Force. Aspirin for the prevention of cardiovascular disease: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2009; 150:396-404.
70. Graham I, Atar D, Borch-Johnsen K et al. European guidelines on cardiovascular disease prevention in clinical practice: executive summary. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). Eur J Cardiovasc Prev Rehabil 2007; 14 Suppl 2:E1-40.
71. World Health Organization. Prevention of Cardiovascular Disease-Guidelines for assessment and management of cardiovascular risk. 2007; 1-86.
72. Eikelboom JW, Hankey GJ. Aspirin resistance: a new independent predictor of vascular events? J Am Coll Cardiol 2003; 41:966-968.
73. Fox KA, Steg PG, Eagle KA et al. Decline in rates of death and heart failure in acute coronary syndromes, 1999-2006. JAMA 2007; 297:1892-1900.
74. Maree AO, Fitzgerald DJ. Variable platelet response to aspirin and clopidogrel in atherothrombotic disease. Circulation 2007; 115:2196-2207.
75. Grove EL, Hvas AM, Kristensen SD. Aspirin resistance: myth or major problem? Scand J Clin Lab Invest 2008; 68:257-259.
76. Kuliczkowski W, Witkowski A, Polonski L et al. Interindividual variability in the response to oral antiplatelet drugs: a position paper of the Working Group on antiplatelet drugs resistance appointed by the Section of Cardiovascular Interventions of the Polish Cardiac Society, endorsed by the Working Group on Thrombosis of the European Society of Cardiology. Eur Heart J 2009; 30:426-435.
77. Snoep JD, Hovens MM, Eikenboom JC et al. Association of laboratory-defined aspirin resistance with a higher risk of recurrent cardiovascular events: a systematic review and meta-analysis. Arch Intern Med 2007; 167:1593-1599.
78. Krasopoulos G, Brister SJ, Beattie WS et al. Aspirin "resistance" and risk of cardiovascular morbidity: systematic review and meta-analysis. BMJ 2008; 336:195-198.
79. Tantry US, Bliden KP, Gurbel PA. Overestimation of platelet aspirin resistance detection by thrombelastograph platelet mapping and validation by conventional aggregometry using arachidonic acid stimulation. J Am Coll Cardiol 2005; 46:1705-1709.
80. Frelinger AL, III, Furman MI, Linden MD et al. Residual arachidonic acid-induced platelet activation via an adenosine diphosphate-dependent but cyclooxygenase-1-and cyclooxygenase-2-independent pathway: a 700-patient study of aspirin resistance. Circulation 2006; 113:2888-2896.
81. Hovens MM, Snoep JD, Eikenboom JC et al. Prevalence of persistent platelet reactivity despite use of aspirin: a systematic review. Am Heart J 2007; 153:175-181.
82. Valles J, Santos MT, Fuset MP et al. Partial inhibition of platelet thromboxane A2 synthesis by aspirin is associated with myonecrosis in patients with STsegment elevation myocardial infarction. Am J Cardiol 2007; 99:19-25.
83. Helgason CM, Tortorice KL, Winkler SR et al. Aspirin response and failure in cerebral infarction. Stroke 1993; 24:345-350.
84. Schwartz KA, Schwartz DE, Ghosheh K et al. Compliance as a critical consideration in patients who appear to be resistant to aspirin after healing of myocardial infarction. Am J Cardiol 2005; 95:973-975.
85. Weber AA, Przytulski B, Schanz A et al. Towards a definition of aspirin resistance: a typological approach. Platelets 2002; 13:37-40.
86. Zimmermann N, Wenk A, Kim U et al. Functional and biochemical evaluation of platelet aspirin resistance after coronary artery bypass surgery. Circulation 2003; 108:542-547.
87. Anger K, Kempfert J, Kostelka M et al. Platelet hyporesponsiveness to acetylsalicylic acid can be transferred by plasma in humans. Pharmacology 2010; 85:241-247.
88. Schmidt M, Maeng M, Jakobsen C et al. Existing data sources for clinical epidemiology: The Western Denmark Heart Registry. Clinical Epidemiology 2010; 2:137-144.
89. Grove EL, Hvas AM, Johnsen HL et al. A comparison of platelet function tests and thromboxane metabolites to evaluate aspirin response in healthy individuals and patients with coronary artery disease. Thromb Haemost 2010; 103:1245-1253.
90. Cutlip DE, Windecker S, Mehran R et al. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation 2007; 115:2344-2351.
91. Grove EL, Hvas AM, Kristensen SD. Platelet function testing in atherothrombotic disease: steps forward in managing resistance to antiplatelet therapy. Polish Heart Journal 2008; 66.
92. Henry P, Vermillet A, Boval B et al. 24-hour timedependent aspirin efficacy in patients with stable coronary artery disease. Thromb Haemost 2010; 105:336-344.
93. Cattaneo M. Laboratory detection of 'aspirin resistance': what test should we use (if any)? Eur Heart J 2007; 28:1673-1675.
94. Brezinski DA, Tofler GH, Muller JE et al. Morning increase in platelet aggregability. Association with assumption of the upright posture. Circulation 1988; 78:35-40.
95. Tofler GH, Brezinski D, Schafer AI et al. Concurrent morning increase in platelet aggregability and the risk of myocardial infarction and sudden cardiac death. N Engl J Med 1987; 316:1514-1518.
96. Editorial [no authors listed]. Diurnal variation in platelet aggregation responses. Lancet 1988; 2:1405-1406.
97. Dalby MC, Davidson SJ, Burman JF et al. Diurnal variation in platelet aggregation iwth the PFA-100 platelet function analyser. Platelets 2000; 11:320-324.
98. Wallen NH, Ladjevardi M, Albert J et al. Influence of different anticoagulants on platelet aggregation in whole blood; a comparison between citrate, low molecular mass heparin and hirudin. Thromb Res 1997; 87:151-157.
99. Kalb ML, Potura L, Scharbert G et al. The effect of ex vivo anticoagulants on whole blood platelet aggregation. Platelets 2009; 20:7-11.
100. Proost JH, Van Imhoff GW, Wesseling H. Plasma levels of acetylsalicylic acid and salicylic acid after oral ingestion of plain and buffered acetylsalicylic acid in relation to bleeding time and thrombocyte function. Pharm Weekbl Sci 1983; 5:22-27.
101. Roberts LJ, Sweetman BJ, Oates JA. Metabolism of thromboxane B2 in man. Identification of twenty urinary metabolites. J Biol Chem 1981; 256:8384-8393.
102. Patrono C, Ciabattoni G, Pugliese F et al. Estimated rate of thromboxane secretion into the circulation of normal humans. J Clin Invest 1986; 77:590-594.
103. FitzGerald GA, Pedersen AK, Patrono C. Analysis of prostacyclin and thromboxane biosynthesis in cardiovascular disease. Circulation 1983; 67:1174-1177.
104. Patrono C, Rocca B. Drug insight: aspirin resistance-fact or fashion? Nat Clin Pract Cardiovasc Med 2007; 4:42-50.
105. Patrono C, Rocca B. Aspirin, 110 years later. J Thromb Haemost 2009; 7 Suppl 1:258-261.
106. Maree AO, Curtin RJ, Dooley M et al. Platelet response to low-dose enteric-coated aspirin in patients with stable cardiovascular disease. J Am Coll Cardiol 2005; 46:1258-1263.
107. Maclouf J, Folco G, Patrono C. Eicosanoids and isoeicosanoids: constitutive, inducible and transcellular biosynthesis in vascular disease. Thromb Haemost 1998; 79:691-705.
108. Eikelboom JW, Hirsh J, Weitz JI et al. Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation 2002; 105:1650-1655.
109. Catella F, FitzGerald GA. Paired analysis of urinary thromboxane B2 metabolites in humans. Thromb Res 1987; 47:647-656.
110. Ciabattoni G, Maclouf J, Catella F et al. Radioimmunoassay of 11-dehydrothromboxane B2 in human plasma and urine. Biochim Biophys Acta 1987; 918:293-297.
111. Thygesen SS. Aspirin resistance evaluated by thromboxane metabolites and platelet aggregation. Research year thesis 2007.
112. Michelson AD, Barnard MR, Krueger LA et al. Circulating monocyte-platelet aggregates are a more sensitive marker of in vivo platelet activation than platelet surface P-selectin: studies in baboons, human coronary intervention, and human acute myocardial infarction. Circulation 2001; 104:1533-1537.
113. McEver RP. Selectins. Curr Opin Immunol 1994; 6:75-84.
114. Morel O, Morel N, Freyssinet JM et al. Platelet microparticles and vascular cells interactions: a checkpoint between the haemostatic and thrombotic responses. Platelets 2008; 19:9-23.
115. Ushiyama S, Laue TM, Moore KL et al. Structural and functional characterization of monomeric soluble Pselectin and comparison with membrane P-selectin. J Biol Chem 1993; 268:15229-15237.
116. Mathur A, Robinson MS, Cotton J et al. Platelet reactivity in acute coronary syndromes: evidence for differences in platelet behaviour between unstable angina and myocardial infarction. Thromb Haemost 2001; 85:989-994.
117. Michelson AD. Platelet function testing in cardiovascular diseases. Circulation 2004; 110:e489-e493.
118. Harrison P, Keeling D. Clinical Tests of Platelet Function. In: Michelson AD, ed. Platelets. Second ed. ed. Academic Press/Elsevier; 2007. p. 445-474.
119. Gasparyan AY, Watson T, Lip GY. The role of aspirin in cardiovascular prevention: implications of aspirin resistance. J Am Coll Cardiol 2008; 51:1829-1843.
120. Bozic-Mijovski M, Rakusa M, Stegnar M. Variation in platelet function testing has a major influence on detection of aspirin resistance in healthy subjects. Pathophysiol Haemost Thromb 2008; 36:84-90.
121. McGlasson DL, Fritsma GA. Whole blood platelet aggregometry and platelet function testing. Semin Thromb Hemost 2009; 35:168-180.
122. BORN GV. Aggregation of blood platelets by adenosine diphosphate and its reversal. Nature 1962; 194:927-929.
123. BORN GV. Quantitative investigations into the aggregation of blood platelets. J Physiol 1962; 67-68.
124. BORN GV, CROSS MJ. The aggregation of blood platelets. J Physiol 1963; 168:178-195.
125. Linnemann B, Schwonberg J, Mani H et al. Standardization of light transmittance aggregometry for monitoring antiplatelet therapy: an adjustment for platelet count is not necessary. J Thromb Haemost 2008; 6:677-683.
126. Gum PA, Kottke-Marchant K, Poggio ED et al. Profile and prevalence of aspirin resistance in patients with cardiovascular disease. Am J Cardiol 2001; 88:230-235.
127. Gum PA, Kottke-Marchant K, Welsh PA et al. A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J Am Coll Cardiol 2003; 41:961-965.
128. Faraday N, Becker DM, Yanek LR et al. Relation between atherosclerosis risk factors and aspirin resistance in a primary prevention population. Am J Cardiol 2006; 98:774-779.
129. Gurbel PA, Bliden KP, DiChiara J et al. Evaluation of dose-related effects of aspirin on platelet function: results from the Aspirin-Induced Platelet Effect (ASPECT) study. Circulation 2007; 115:3156-3164.
130. Lordkipanidze M, Pharand C, Schampaert E et al. A comparison of six major platelet function tests to determine the prevalence of aspirin resistance in patients with stable coronary artery disease. Eur Heart J 2007; 28:1702-1708.
131. Muir AR, McMullin MF, Patterson C et al. Assessment of aspirin resistance varies on a temporal basis in patients with ischaemic heart disease. Heart 2009; 95:1225-1229.
132. Matetzky S, Shenkman B, Guetta V et al. Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation 2004; 109:3171-3175.
133. Gurbel PA, Bliden KP, Guyer K et al. Platelet reactivity in patients and recurrent events post-stenting: results of the PREPARE POST-STENTING Study. J Am Coll Cardiol 2005; 46:1820-1826.
134. Cuisset T, Frere C, Quilici J et al. High post-treatment platelet reactivity identified low-responders to dual antiplatelet therapy at increased risk of recurrent cardiovascular events after stenting for acute coronary syndrome. J Thromb Haemost 2006; 4:542-549.
135. Hochholzer W, Trenk D, Bestehorn HP et al. Impact of the degree of peri-interventional platelet inhibition after loading with clopidogrel on early clinical outcome of elective coronary stent placement. J Am Coll Cardiol 2006; 48:1742-1750.
136. Buonamici P, Marcucci R, Migliorini A et al. Impact of platelet reactivity after clopidogrel administration on drug-eluting stent thrombosis. J Am Coll Cardiol 2007; 49:2312-2317.
137. Hayward CP, Moffat KA, Raby A et al. Development of North American consensus guidelines for medical laboratories that perform and interpret platelet function testing using light transmission aggregometry. Am J Clin Pathol 2010; 134:955-963.
138. Nicholson NS, Panzer-Knodle SG, Haas NF et al. Assessment of platelet function assays. Am Heart J 1998; 135:S170-S178.
139. Collet JP, Werkum JWv. Individualised Antiplatelet Therapy-Is There a Role for Platelet Function Testing in Routine Clinical Practice? European Cardiology 2010; 6:41-49.
140. Stegnar M, Knezevic A, Bozic-Mijovski M. The effect of pre-analytical variables on light transmittance aggregometry in citrated platelet-rich plasma from healthy subjects. Clin Chem Lab Med 2010; 48:1463-1465.
141. Jilma B. Platelet function analyzer (PFA-100): a tool to quantify congenital or acquired platelet dysfunction. J Lab Clin Med 2001; 138:152-163.
142. Crescente M, Di CA, Iacoviello L et al. PFA-100 closure time to predict cardiovascular events in aspirin-treated cardiovascular patients: A meta-analysis of 19 studies comprising 3,003 patients. Thromb Haemost 2008; 99:1129-1131.
143. Madsen EH, Schmidt EB, Gehr N et al. Testing aspirin resistance using the Platelet Function Analyzer-100: some methodological caveats and considerations. J Thromb Haemost 2008; 6:386-388.
144. Garvey B, Mahon A, McTaggert P et al. The Sysmex XE-2100™ haematology analyser. Medicines and Healthcare products Regulatory Agency (MHRA) report no 03058, 2003; 1-104.
145. Tsuruda K, Tsuji T, Usui T et al. Evaluation and Clinical Usefulness of the Automated Hematology Analyzer, Sysmex XE-2100™. Sysmex Journal International 1999; 9:129-138.
146. Briggs C, Kunka S, Machin SJ. The most accurate platelet count on the Sysmex XE-2100. Optical or impedance? Clin Lab Haematol 2004; 26:157-158.
147. Briggs C, Hart D, Kunka S et al. Immature platelet fraction measurement: a future guide to platelet transfusion requirement after haematopoietic stem cell transplantation. Transfus Med 2006; 16:101-109.
148. Albanyan A, Murphy MF, Wilcock M et al. Changes in the immature platelet fraction within ageing platelet concentrates. J Thromb Haemost 2008; 6:2213-2215.
149. Ruisi MM, Psaila B, Ward MJ et al. Stability of measurement of the immature platelet fraction. Am J Hematol 2010; 85:622-624.
150. Kienast J, Schmitz G. Flow cytometric analysis of thiazole orange uptake by platelets: a diagnostic aid in the evaluation of thrombocytopenic disorders. Blood 1990; 75:116-121.
151. Chavda N, Mackie IJ, Porter JB et al. Rapid flow cytometric quantitation of reticulated platelets in whole blood. Platelets 1996; 7:189-194.
152. Kickler TS, Oguni S, Borowitz MJ. A clinical evaluation of high fluorescent platelet fraction percentage in thrombocytopenia. Am J Clin Pathol 2006; 125:282-287.
153. Hinzmann R. The Clinical Utility of the Quantification of Immature Platelets. Haematologica (edicion espanola) 2006; 91(Supl 1):149-153.
154. Robinson MS, Mackie IJ, Khair K et al. Flow cytometric analysis of reticulated platelets: evidence for a large proportion of non-specific labelling of dense granules by fluorescent dyes. Br J Haematol 1998; 100:351-357.
155. Kalkman H. XE-IPF MASTER-optional software module for XE-2100. 2005 Jun 15.
156. Koike Y, Miyazaki K, Higashihara M et al. Clinical significance of detection of immature platelets: comparison between percentage of reticulated platelets as detected by flow cytometry and immature platelet fraction as detected by automated measurement. Eur J Haematol 2010; 84:183-184.
157. Pons I, Monteagudo M, Lucchetti G et al. Correlation between immature platelet fraction and reticulated platelets. Usefulness in the etiology diagnosis of thrombocytopenia. Eur J Haematol 2010; 85:158-163.
158. de Vries RA, de BM, Marx JJ et al. Radioisotopic labels for blood cell survival studies: a review. Nucl Med Biol 1993; 20:809-817.
159. Steinberg MH, Kelton JG, Coller BS. Plasma glycocalicin. An aid in the classification of thrombocytopenic disorders. N Engl J Med 1987; 317:1037-1042.
160. Yamaoka G, Kubota Y, Nomura T et al. The immature platelet fraction is a useful marker for predicting the timing of platelet recovery in patients with cancer after chemotherapy and hematopoietic stem cell transplantation. Int J Lab Hematol 2010; 32:e208-e216.
161. Bowles KM, Cooke LJ, Richards EM et al. Platelet size has diagnostic predictive value in patients with thrombocytopenia. Clin Lab Haematol 2005; 27:370-373.
162. Siller-Matula JM, Gouya G, Wolzt M et al. Cross validation of the Multiple Electrode Aggregometry. A prospective trial in healthy volunteers. Thromb Haemost 2009; 102:397-403.
163. Wenaweser P, Dorffler-Melly J, Imboden K et al. Stent thrombosis is associated with an impaired response to antiplatelet therapy. J Am Coll Cardiol 2005; 45:1748-1752.
164. Poulsen TS, Mickley H, Korsholm L et al. Using the Platelet Function Analyzer-100 for monitoring aspirin therapy. Thromb Res 2006; 120:161-172.
165. thHemophilia Symposium Hamburg 2005. Springer Berlin Heidelberg; 2007. p. 243-251.
166. Grove EL, Hvas AM, Kristensen SD. Immature platelets in patients with acute coronary syndromes. Thromb Haemost 2009; 101:151-156.
167. Grove EL, Hvas AM, Mortensen SB et al. Effect of platelet turnover on whole blood platelet aggregation in patients with coronary artery disease. J Thromb Haemost 2011; 9:185-191.
168. Mortensen SB, Larsen SB, Grove EL et al. Reduced platelet response to aspirin in patients with coronary artery disease and type 2 diabetes mellitus. Thromb Res 2010; 126:e318-e322.
169. Anfossi G, Russo I, Trovati M. Resistance to aspirin and thienopyridines in diabetes mellitus and metabolic syndrome. Curr Vasc Pharmacol 2008; 6:313-328.
170. Ferreiro JL, Cequier AR, Angiolillo DJ. Antithrombotic therapy in patients with diabetes mellitus and coronary artery disease. Diab Vasc Dis Res 2010; 7:274-288.
171. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E et al. Platelet function profiles in patients with type 2 diabetes and coronary artery disease on combined aspirin and clopidogrel treatment. Diabetes 2005; 54:2430-2435.
172. Wurtz M, Grove EL, Wulff LN et al. Patients with previous definite stent thrombosis have a reduced antiplatelet effect of aspirin and a larger fraction of immature platelets. JACC Cardiovasc Interv 2010; 3:828-835.
173. Cotter G, Shemesh E, Zehavi M et al. Lack of aspirin effect: aspirin resistance or resistance to taking aspirin? Am Heart J 2004; 147:293-300.
174. Glynn RJ, Buring JE, Manson JE et al. Adherence to aspirin in the prevention of myocardial infarction. The Physicians' Health Study. Arch Intern Med 1994; 154:2649-2657.
175. Cuisset T, Frere C, Quilici J et al. Aspirin noncompliance is the major cause of "aspirin resistance" in patients undergoing coronary stenting. Am Heart J 2009; 157:889-893.
176. Dalen JE. Aspirin resistance: is it real? Is it clinically significant? Am J Med 2007; 120:1-4.
177. Cheng X, Chen WH, Simon DI. Aspirin resistance or variable response or both? Am J Cardiol 2006; 98:S11-S17.
178. Lam JY, Latour JG, Lesperance J et al. Platelet aggregation, coronary artery disease progression and future coronary events. Am J Cardiol 1994; 73:333-338.
179. Kabbani SS, Watkins MW, Ashikaga T et al. Platelet reactivity characterized prospectively: a determinant of outcome 90 days after percutaneous coronary intervention. Circulation 2001; 104:181-186.
180. Marcucci R, Gori AM, Paniccia R et al. High ontreatment platelet reactivity by more than one agonist predicts 12-month follow-up cardiovascular death and non-fatal myocardial infarction in acute coronary syndrome patients receiving coronary stenting. Thromb Haemost 2010; 104:279-286.
181. Hankey GJ, Eikelboom JW. Aspirin resistance. Lancet 2006; 367:606-617.
182. Serebruany VL, Steinhubl SR, Berger PB et al. Variability in platelet responsiveness to clopidogrel among 544 individuals. J Am Coll Cardiol 2005; 45:246-251.
183. Violi F, Pignatelli P. The need for a consistent definition of "aspirin resistance". J Thromb Haemost 2006; 4:1618-1619.
184. Svenstrup PT, Risom KS, Atar D et al. A critical appraisal of the phenomenon of aspirin resistance. Cardiology 2005; 104:83-91.
185. Alberts MJ. Platelet Function Testing for Aspirin Resistance Is Reasonable to Do. Yes! Stroke 2010; 41:2400-2401.
186. Frelinger AL, III, Li Y, Linden MD et al. Association of cyclooxygenase-1-dependent and-independent platelet function assays with adverse clinical outcomes in aspirin-treated patients presenting for cardiac catheterization. Circulation 2009; 120:2586-2596.
187. Santilli F, Rocca B, De CR et al. Platelet cyclooxygenase inhibition by low-dose aspirin is not reflected consistently by platelet function assays: implications for aspirin "resistance". J Am Coll Cardiol 2009; 53:667-677.
188. Watala C, Golanski J, Pluta J et al. Reduced sensitivity of platelets from type 2 diabetic patients to acetylsalicylic acid (aspirin)-its relation to metabolic control. Thromb Res 2004; 113:101-113.
189. Mammen EF, Comp PC, Gosselin R et al. PFA-100 system: a new method for assessment of platelet dysfunction. Semin Thromb Hemost 1998; 24:195-202.
190. Homoncik M, Jilma B, Hergovich N et al. Monitoring of aspirin (ASA) pharmacodynamics with the platelet function analyzer PFA-100. Thromb Haemost 2000; 83:316-321.
191. Seyfert UT, Haubelt H, Vogt A et al. Variables influencing Multiplate(TM) whole blood impedance platelet aggregometry and turbidimetric platelet aggregation in healthy individuals. Platelets 2007; 18:199-206.
192. Chakroun T, Gerotziafas G, Robert F et al. In vitro aspirin resistance detected by PFA-100 closure time: pivotal role of plasma von Willebrand factor. Br J Haematol 2004; 124:80-85.
193. Hanke AA, Roberg K, Monaca E et al. Impact of Platelet Count on Results Obtained from Multiple Electrode Platelet Aggregometry (Multiplate supersetTE). Eur J Med Res 2010; 15:214-219.
194. Malinin A, Spergling M, Muhlestein B et al. Assessing aspirin responsiveness in subjects with multiple risk factors for vascular disease with a rapid platelet function analyzer. Blood Coagul Fibrinolysis 2004; 15:295-301.
195. Karha J, Rajagopal V, Kottke-Marchant K et al. Lack of effect of enteric coating on aspirin-induced inhibition of platelet aggregation in healthy volunteers. Am Heart J 2006; 151:976-11.
196. Paniccia R, Antonucci E, Gori AM et al. Comparison of different methods to evaluate the effect of aspirin on platelet function in high-risk patients with ischemic heart disease receiving dual antiplatelet treatment. Am J Clin Pathol 2007; 128:143-149.
197. Lee PY, Chen WH, Ng W et al. Low-dose aspirin increases aspirin resistance in patients with coronary artery disease. Am J Med 2005; 118:723-727.
198. Blais N, Pharand C, Lordkipanidze M et al. Response to aspirin in healthy individuals. Cross-comparison of light transmission aggregometry, VerifyNow system, platelet count drop, thromboelastography (TEG) and urinary 11-dehydrothromboxane B(2). Thromb Haemost 2009; 102:404-411.
199. Frelinger AL, Li Y, Linden MD et al. Aspirin 'resistance': role of pre-existent platelet reactivity and correlation between tests. J Thromb Haemost 2008; 6:2035-2044.
200. Renda G, Zurro M, Malatesta G et al. Inconsistency of different methods for assessing ex vivo platelet function: relevance for the detection of aspirin resistance. Haematologica 2010; 95:2095-2101.
201. Di MG, Silver MJ, Murphy S. Monitoring the entry of new platelets into the circulation after ingestion of aspirin. Blood 1983; 61:1081-1085.
202. Reilly IA, FitzGerald GA. Inhibition of thromboxane formation in vivo and ex vivo: implications for therapy with platelet inhibitory drugs. Blood 1987; 69:180-186.
203. Yee DL, Sun CW, Bergeron AL et al. Aggregometry detects platelet hyperreactivity in healthy individuals. Blood 2005; 106:2723-2729.
204. Angiolillo DJ, Bernardo E, Sabate M et al. Impact of platelet reactivity on cardiovascular outcomes in patients with type 2 diabetes mellitus and coronary artery disease. J Am Coll Cardiol 2007; 50:1541-1547.
205. Simon DI, Schmaier AH. Sweet and sticky: diabetic platelets, enhanced reactivity, and cardiovascular risk. J Am Coll Cardiol 2007; 50:1548-1550.
206. Lev EI, Patel RT, Maresh KJ et al. Aspirin and clopidogrel drug response in patients undergoing percutaneous coronary intervention: the role of dual drug resistance. J Am Coll Cardiol 2006; 47:27-33.
207. Dharmasaroja PA, Sae-Lim S. Effects of different doses, enteric-coated preparation of aspirin, and sex on urinary 11-dehydrothromboxane B2 in healthy volunteers. Blood Coagul Fibrinolysis 2010; 21:649-652.
208. Alberts MJ, Bergman DL, Molner E et al. Antiplatelet effect of aspirin in patients with cerebrovascular disease. Stroke 2004; 35:175-178.
209. Catella-Lawson F, Reilly MP, Kapoor SC et al. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med 2001; 345:1809-1817.
210. Malinin AI, Ong S, Makarov LM et al. Platelet inhibition beyond conventional antiplatelet agents: expanding role of angiotensin receptor blockers, statins and selective serotonin reuptake inhibitors. Int J Clin Pract 2006; 60:993-1002.
211. Tran HA, Anand SS, Hankey GJ et al. Aspirin resistance. Thromb Res 2007; 120:337-346.
212. Charlot M, Grove EL, Hansen PR et al. Proton pump inhibitor use and risk of adverse cardiovascular events in aspirin treated patients with first time myocardial infarction: nationwide propensity score matched study. BMJ 2011; 342:d2690.
213. O'Donnell CJ, Larson MG, Feng D et al. Genetic and environmental contributions to platelet aggregation: the Framingham heart study. Circulation 2001; 103:3051-3056.
214. Maree AO, Curtin RJ, Chubb A et al. Cyclooxygenase-1 haplotype modulates platelet response to aspirin. J Thromb Haemost 2005; 3:2340-2345.
215. Cipollone F, Toniato E, Martinotti S et al. A polymorphism in the cyclooxygenase 2 gene as an inherited protective factor against myocardial infarction and stroke. JAMA 2004; 291:2221-2228.
216. Feher G, Feher A, Pusch G et al. The genetics of antiplatelet drug resistance. Clin Genet 2009; 75:1-18.
217. Storey RF. Clopidogrel in acute coronary syndrome: to genotype or not? Lancet 2009; 373:276-278.
218. Pamukcu B, Oflaz H, Oncul A et al. The role of aspirin resistance on outcome in patients with acute coronary syndrome and the effect of clopidogrel therapy in the prevention of major cardiovascular events. J Thromb Thrombolysis 2006; 22:103-110.
219. Shantsila E, Watson T, Lip GY. Aspirin resistance: What, why and when? Thromb Res 2006; 119:551-555.
220. Mateos-Caceres PJ, Macaya C, Azcona L et al. Different expression of proteins in platelets from aspirin-resistant and aspirin-sensitive patients. Thromb Haemost 2010; 103:160-170.
221. Lordkipanidze M, Diodati JG, Turgeon J et al. Platelet count, not oxidative stress, may contribute to inadequate platelet inhibition by aspirin. Int J Cardiol 2010; 143:43-50.
222. Mangalpally KK, Siqueiros-Garcia A, Vaduganathan M et al. Platelet activation patterns in platelet size subpopulations: differential responses to aspirin in vitro. J Thromb Thrombolysis 2010; 30:251-262.
223. Lakkis N, Dokainish H, Abuzahra M et al. Reticulated platelets in acute coronary syndrome: a marker of platelet activity. J Am Coll Cardiol 2004; 44:2091-2093.
224. Gonzalez-Porras JR, Martin-Herrero F, Gonzalez-Lopez TJ et al. The role of immature platelet fraction in acute coronary syndrome. Thromb Haemost 2010; 103:247-249.
225. Kristensen SD, Bath PM, Martin JF. Differences in bleeding time, aspirin sensitivity and adrenaline between acute myocardial infarction and unstable angina. Cardiovasc Res 1990; 24:19-23.
226. Kristensen SD, Milner PC, Martin JF. Bleeding time and platelet volume in acute myocardial infarction-a 2 year follow-up study. Thromb Haemost 1988; 59:353-356.
227. Harrison P, Mackie I, Mathur A et al. Platelet hyperfunction in acute coronary syndromes. Blood Coagul Fibrinolysis 2005; 16:557-562.
228. Poulsen TS, Kristensen SR, Korsholm L et al. Variation and importance of aspirin resistance in patients with known cardiovascular disease. Thromb Res 2007; 120:477-484.
229. Frossard M, Fuchs I, Leitner JM et al. Platelet function predicts myocardial damage in patients with acute myocardial infarction. Circulation 2004; 110:1392-1397.
230. Borna C, Lazarowski E, van HC et al. Resistance to aspirin is increased by ST-elevation myocardial infarction and correlates with adenosine diphosphate levels. Thromb J 2005; 3:10.
231. Rinder HM, Schuster JE, Rinder CS et al. Correlation of thrombosis with increased platelet turnover in thrombocytosis. Blood 1998; 91:1288-1294.
232. Macaulay IC, Carr P, Gusnanto A et al. Platelet genomics and proteomics in human health and disease. J Clin Invest 2005; 115:3370-3377.
233. Evangelista V, Manarini S, Di SA et al. De novo synthesis of cyclooxygenase-1 counteracts the suppression of platelet thromboxane biosynthesis by aspirin. Circ Res 2006; 98:593-595.
234. Weber AA, Zimmermann KC, Meyer-Kirchrath J et al. Cyclooxygenase-2 in human platelets as a possible factor in aspirin resistance. Lancet 1999; 353:900.
235. FitzGerald GA, Brash AR, Oates JA et al. Endogenous prostacyclin biosynthesis and platelet function during selective inhibition of thromboxane synthase in man. J Clin Invest 1983; 72:1336-1343.
236. Luscher TF, Creager MA, Beckman JA et al. Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: Part II. Circulation 2003; 108:1655-1661.
237. Beckman JA, Creager MA, Libby P. Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. JAMA 2002; 287:2570-2581.
238. Haffner SM, Lehto S, Ronnemaa T et al. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998; 339:229-234.
239. Creager MA, Luscher TF, Cosentino F et al. Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: Part I. Circulation 2003; 108:1527-1532.
240. Serebruany V, Pokov I, Kuliczkowski W et al. Baseline platelet activity and response after clopidogrel in 257 diabetics among 822 patients with coronary artery disease. Thromb Haemost 2008; 100:76-82.
241. Watala C, Pluta J, Golanski J et al. Increased protein glycation in diabetes mellitus is associated with decreased aspirin-mediated protein acetylation and reduced sensitivity of blood platelets to aspirin. J Mol Med 2005; 83:148-158.
242. Belch J, MacCuish A, Campbell I et al. The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease. BMJ 2008; 337:a1840.
243. Ogawa H, Nakayama M, Morimoto T et al. Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial. JAMA 2008; 300:2134-2141.
244. De BG, Sacco M, Strippoli GF et al. Aspirin for primary prevention of cardiovascular events in people with diabetes: meta-analysis of randomised controlled trials. BMJ 2009; 339:b4531.
245. Tschoepe D, Roesen P, Esser J et al. Large platelets circulate in an activated state in diabetes mellitus. Semin Thromb Hemost 1991; 17:433-438.
246. Brown AS, Hong Y, de BA et al. Megakaryocyte ploidy and platelet changes in human diabetes and atherosclerosis. Arterioscler Thromb Vasc Biol 1997; 17:802-807.
247. Watala C, Boncler M, Pietrucha T et al. Possible mechanisms of the altered platelet volume distribution in type 2 diabetes: does increased platelet activation contribute to platelet size heterogeneity? Platelets 1999; 10:52-60.
248. Watala C, Boncler M, Gresner P. Blood platelet abnormalities and pharmacological modulation of platelet reactivity in patients with diabetes mellitus. Pharmacol Rep 2005; 57 Suppl:42-58.
249. DiMinno G, Silver MJ, Cerbone AM et al. Trial of repeated low-dose aspirin in diabetic angiopathy. Blood 1986; 68:886-891.
250. van Werkum JW, Topcu Y, Postma S et al. Effects of diabetes mellitus on platelet reactivity after dual antiplatelet therapy with aspirin and clopidogrel. Thromb Haemost 2008; 99:637-639.
251. DiChiara J, Bliden KP, Tantry US et al. The effect of aspirin dosing on platelet function in diabetic and nondiabetic patients: an analysis from the aspirininduced platelet effect (ASPECT) study. Diabetes 2007; 56:3014-3019.
252. Sideris G, Guyetand C, Belluci S et al. Low dose aspirin does not maintain a 24-hour biological efficacy in type-2 diabetic patients. Eur Heart J 2007; 28 Suppl:267.
253. Toth O, Calatzis A, Penz S et al. Multiple electrode aggregometry: a new device to measure platelet aggregation in whole blood. Thromb Haemost 2006; 96:781-788.
254. Johnson A, Dovlatova N, Heptinstall S. Multiple electrode aggregometry and P2Y(12) antagonists. Thromb Haemost 2008; 99:1127-1129.
255. Packham MA, Kinlough-Rathbone RL, Mustard JF. Thromboxane A2 causes feedback amplification involving extensive thromboxane A2 formation on close contact of human platelets in media with a low concentration of ionized calcium. Blood 1987; 70:647-651.
256. Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1986; 1:307-310.
257. Price MJ, Berger PB, Angiolillo DJ et al. Evaluation of individualized clopidogrel therapy after drug-eluting stent implantation in patients with high residual platelet reactivity: design and rationale of the GRAVITAS trial. Am Heart J 2009; 157:818-24, 824.
258. Pettersen AA, Seljeflot I, Abdelnoor M et al. Unstable angina, stroke, myocardial infarction and death in aspirin non-responders. A prospective, randomized trial. The ASCET (ASpirin non-responsiveness and Clopidogrel Endpoint Trial) design. Scand Cardiovasc J 2004; 38:353-356.